DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pretomanid
Pretomanid
Clofazimine As a Treatment for Multidrug-Resistant Tuberculosis: a Review
Inhaled Anti-Tubercular Therapy: Dry Powder Formulations, Device And
Treatment of Drug-Resistant Tuberculosis an Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R
Pretomanid Reference Number: CP.PMN.222 Effective Date: 03.01.20 Last Review Date: 02.20 Line of Business: Commercial, HIM, Medicaid Revision Log
Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations
Appraisal of NICE's Cost-Effectiveness Thresholds for Assessing Orphan
Orphan Maintenance Assessment Report
Full Text Article
Mechanisms of Drug Resistance in Mycobacterium Tuberculosis: Update 2015
U.S. Food and Drug Administration (FDA) Approves Pretomanid
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Evolution of Drug Resistance in Mycobacterium Tuberculosis: a Review on the Molecular Determinants of Resistance and Implications for Personalized Care
Regimens to Treat Multidrug-Resistant Tuberculosis: Past, Present and Future Perspectives
Volume 16 Issue 1 Four-Month Rifapentine Regimens with Or
FDA Briefing Document Pretomanid
Antitubercular Drugs Pdf
CYCLOSERINE, PRETOMANID and SIRTURO®
Medicaid List of Covered Drugs (Formulary)
Top View
WHO Consolidated Guidelines on Tuberculosis WHO Operational
Pretomanid Prescribing Information
PA-824) Baptista, Rafael; Fazakerley, David M.; Beckmann, Manfred; Baillie, Les; Mur, Luis A
Morphological Profiling of Tubercle Bacilli Identifies Drug Pathways of Action
Untargeted Metabolomics Reveals a New Mode of Action of Pretomanid (PA-824) Received: 2 November 2017 Rafael Baptista 1, David M
Pretomanid Tablet Drug Class: Antimycobacterial Agent Prepared For: MO Healthnet Prepared By: Conduent
Guide to Antimicrobial Chemotherapy (PDF)
Pretomanid with Bedaquiline and Linezolid for Drug- Resistant TB: a Comparison of Prospective Cohorts
Exposure References Conclusions Methods Results
Pretomanid EOCCO POLICY
An Activist's Guide to Treatment for Drug
212862Orig1s000 OTHER REVIEW(S)
Breaking Resistance
Assessment Report
Cigna Performance 3-Tier Prescription Drug List
Dr-Tb & Tb-Prevention Drugs Under the Microscope
Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR/RR-TB)
Avis De Transparence Sirturo 100 Mg Comprimé
Prescription Drug List/Formulary
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
Potency Boost of a Mycobacterium Tuberculosis Dihydrofolate Reductase Inhibitor by Multienzyme F420H2-Dependent Reduction
Multi-Omics Technologies Applied to Tuberculosis Drug Discovery
Pretomanid Reference Number: ERX.NPA.131 Effective Date: 03.01.20 Last Review Date: 05.21 Line of Business: Commercial, Medicaid Revision Log
Co-Administration of Pretomanid with Rifampin Or Rifabutin Among Patients with Pulmonary Tuberculosis
Pretomanid FGK, INN-Pretomanid
Pretomanid and Bpal Regimen for Treatment of Highly-Resistant Tuberculosis
Drug-Resistant Tuberculosis: a Survival Guide for Clinicians
212862Orig1s000 LABELING
FDA Introductory Comments
Pretomanid Sponsor Briefing Document Antimicrobial Drugs
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
New Drugs for the Treatment of Tuberculosis